Intra-fractional dosimetric analysis of image-guided adaptive intracavitary brachytherapy of cervical cancer

Junfang Yan

Peking Union Medical College Hospital

Jiawei Zhu

Peking Union Medical College Hospital <https://orcid.org/0000-0001-5708-6704>

Kai Chen

Sun Yat-sen University Cancer Center

Lang Yu

Peking Union Medical College Hospital

Fuquan Zhang (✉ zhangfuquan3@126.com)

Chinese Academe of Medical Sciences & Peking Union Medical College

Research

Keywords: Cone beam computed tomography, image-guided adaptive intracavitary brachytherapy, intra-fractional variation, cervical cancer

Posted Date: February 5th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-191283/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Radiation Oncology on August 4th, 2021. See the published version at <https://doi.org/10.1186/s13014-021-01870-x>.

Abstract

Background

To assess the intra-fractional dosimetric variations of image-guided adaptive brachytherapy of cervical cancer.

Methods

A total of 38 fractions (9 patients) undergoing brachytherapy for cervical cancer underwent a CT scanning for treatment planning (planning CT) and a CBCT scanning immediately prior to treatment (pre-treatment CBCT). Variations between images acquired within one applicator insertions (intra-application) were evaluated. The DVH parameters including volume, D90 HRCTV and D2cc OARs were recorded.

Results

The variations (mean $\pm$ SD) of the volume and D90 HRCTV are $-2.00 \pm 3.26\%$ and $-1.18 \pm 4.47\%$, respectively. The variations of D2cc for bladder, rectum, sigmoid and small intestine are $-0.6 \pm 17.05\%$, $9.34 \pm 14.59\%$, $7.15\% \pm 20.49\%$ and $1.52 \pm 12.57\%$, respectively. Most of them are statistically nonsignificant except the D2cc for rectum, which showed a significant increase ($P = 0.001$). Using 5% and 10% uncertainty of physical dose for HRCTV at a 6Gy $\cdot$ 5 HDR schedule, the possibility of total EQD2 dose lower than 85Gy is close to 0% and 3%, respectively. Performing similar simulation at 15% and 20% uncertainty of a 4Gy physical dose for OARs, the possibility of total EQD2 dose exceeding 75Gy is about 70%. Less than 1% of the total EQD2 of OARs would exceed 80Gy.

Conclusions

Average intra-fractional dosimetric variation of HRCTV was small in a interval of less than 1 hour, and the possibility of total EQD2 exceeding 85Gy is higher than 97%. The intra-fractional dosimetric variations of OARs might result in an overdose for OARs in a single fraction or the whole treatment. It is necessary to detect unfavorable anatomical changes by re-imaging and take interventions to minimize applied doses and reduce the risk of complications.

Introduction

Radiotherapy is an essential component of curative treatment of locally advanced cervical cancer, which includes external beam radiotherapy (EBRT) and brachytherapy (BT) [1]. Based on detailed information of the anatomical situation and applicator position, three-dimensional image-guided adaptive brachytherapy (3D-IGABT) achieves the precise planning with improved disease control, overall survival (OS) and complications over conventional brachytherapy [2–5]. Although MRI-based IGABT is a gold standard for

cervical cancer [6], CT-based planning provides useful information, such as applicator position or delineating the organ at risk (OAR), which is comparable with MRI [7]. In addition, CT-based 3D-IGABT is easier to achieve due to the popularity of CT simulators in most medical centers [7–10]. With the help of one pre- or at brachytherapy MRI to access tumor extension, CT-based 3D-IGABT can be much more accurate in cervical cancer brachytherapy, and be an alternative when MRI is difficult to achieve [7, 11]. However, the effect of intra-fractional variation remains an issue in IGABT for cervical cancer [12]. These intra-fractional target and OARs variations might result from changes in location relative to the applicator, variations of shape and/or filling status of organs at risk (OAR), and patient transfer. Several studies have reported the intra-fractional dosimetric variations in the IGABT for cervical cancer, which might require repetitive imaging and predelivery intervention treatment [12–15].

Two common approaches used in the reported studies to calculate the applied dose are based on repetitive scanning with CT imaging[12, 15], and MRI imaging[13, 14, 16]. In most trials, patients are usually transferred from the brachytherapy suite to CT/MRI unit for repetitive scanning. CBCT is a popular imaging method that provides valuable 3D information of the patient for treatment verification and plan of the day selection [17, 18]. Although CBCT exhibits a lower soft tissue contrast than CT, the main advantage of using CBCT is the capability of performing pre-delivery scan without transferring the patient from the CT unit to the brachytherapy suite. Limiting the patient's motion is expected to limit postinsertion applicator motion, which in return provides real-time anatomical information and leads to more accurate calculation of the applied dose. In previous studies, CBCT with/without ultrasound was successfully utilized for 3D planning in high-dose-rate (HDR) BT for cervical cancer [19, 20]. Recent studies tried to calculate the applied dose based on CT-to-CBCT using deformable image registration algorithms (DIR) or directly calculation [21–23].

As far as we know, this was the first study to analyze and quantify intra-fractional variation of the HRCTV and OARs based on planning CT and pre-delivery CBCT for brachytherapy. Pre-delivery CBCT data are used to investigate fluctuations in the applied dose distributions as compared to the dose distribution on planning CT. The HRCTV and OARs were contoured on the pre-delivery CBCT that were taken before each treatment, and the applied to these organs was assessed based on the patient's real-time anatomy.

Method

Patients

A total of 9 patients were selected for the study according to the following criteria: A) The pelvic MRI scan was completed at the time of diagnosis and the first-fraction of brachytherapy. B) No previous history of abdominal and pelvic surgery. The cancer was classified as FIGO Stage IB1 for 2 patients, Stage IIA for 2 patients, Stage IIB for 4 patients, and Stage IIIB for 1 patient.

Treatments

EBRT was delivered by intensity modulated radiation therapy to the whole pelvis, and a dose of 50.4Gy in 28 fractions was delivered over a period of 5½ weeks. All the patients received five sessions of high-dose-rate ^{192}Ir brachytherapy, which was usually administered twice per week. Consequently, 38 fractions of brachytherapy were available for this study. In principle, the prescribed dose was 6Gy at HRCTV in each brachytherapy session. A separate insertion was used for each fraction with the Fletcher/Utrecht CT/MR applicator (Elekta, Stockholm, Sweden). The applicator was inserted into the vagina, and wet gauze was then packed on its anterior and posterior sides. During the insertion, the patients were placed on a bed board, and a fixation device was used to fix the applicator firmly to the bed board to reduce the movement of the applicator during patient transfer. A Foleys catheter was inserted for consistent drainage, ensuring an empty bladder. All patients were asked to defecate before insertion and no rectal tubes were inserted.

The CT image for treatment planning (the pre-delivery CT) was obtained at 2.5 mm thickness after the insertion of the applicator, using the Brilliance CT Big Bore (Philips Healthcare, Best, the Netherlands). The HRCTV and OARs (bladder, rectum, sigmoid, and small intestine) were then contoured according to Groupe Européen de Curiethérapie and European Society for Radiotherapy Oncology (GEC-ESTRO) recommendations using MRI as a reference cognitively [24, 25]. The treatment plan for IGABT based on the pre-delivery CT was then created; this was then approved by an experienced medical physicist and a radiation oncologist. The treatment planning system used for the brachytherapy was Oncentra version 4.1 software (Elekta, Stockholm, Sweden), and the dose was optimized by using inverse planning simulated annealing algorithm and manual optimization. After the completion of the CT-based treatment planning, patients were transferred to the brachytherapy suite and moved to the Trilogy linear accelerator (Varian Medical Systems, California, USA). Immediately after obtaining pre-delivery CBCT image at 2.5 mm thickness, the dose was delivered in situ.

Dose and DVH evaluation of planning CT and pre-delivery CBCT

Volume, The D90 HRCTV, and D2cc of the OARs were calculated [26]. The brachytherapy dose was converted into the biological equivalent dose in 2Gy daily fractions (EQD2) using the linear model with $a/b = 10\text{Gy}$ for HR-CTV and $a/b = 3\text{ Gy}$ for OARs [27]. The dose constraints were $\text{D2cc} < 90\text{Gy}$ for the bladder, $\text{D2cc} < 75\text{Gy}$ for the rectum, sigmoid and small intestine.

Re-calculation of the dose to the HRCTV and OARs at pre-delivery CBCT was performed. The planning CT and pre-delivery CBCT images were imported into the Eclipse version 8.6 software (Varian Medical Systems, Palo Alto, CA, USA), and both images were rigidly fused by matching the inserted applicator as a fiducial marker. Pairs of scans were registered, relative to the applicator. The original contours of planning CT were re-sampled on pre-delivery CBCT. The contours were adapted according to the anatomy visible on the pre-delivery CBCT. The planned dose was mapped onto the pre-delivery CBCT; the planning CT dose placed on the pre-delivery CBCT was regarded as the applied dose. A single experienced observer reviewed all contours to reduce inter-observer contouring variation. D90 HRCTV and D2cc OARs values of the adapted contours were determined and converted to EQD2. Structure volumes were also calculated on

the basis of the contouring of the rectum, bladder, sigmoid and small intestine. Percentage differences in structure volumes and DVH parameters were calculated using the following formula:

$$\text{Difference}(\%) = \frac{\text{Value}_{\text{plan}} - \text{Value}_{\text{pre}}}{\text{Value}_{\text{plan}}} \times 100$$

We analyzed the mean and variability of the dosimetric difference and DVH value calculated for all cases, for each patient and for each fraction, and we also analyzed the trends. In order to evaluate the clinical importance of the observed dosimetric uncertainties, typical clinical scenarios for an HDR BT treatment were simulated to assess the effect of uncertainties on total accumulated dose. The EQD2 of external irradiation is 49.56Gy (50.4Gy in 28 fractions) and five HDR BT of 6Gy was delivered. 4,000 simulations were run according to a N (di, σ²) distribution, where di was the physical fractional dose and σ was the standard deviation (SD) of intra-application variations for target or OAR [14]. Relevant σ levels were chosen according to the uncertainty level of D90 HRCTV and D2cc OARs in our study, as shown in Table 1 : 5% and 10% for D90 HRCTV, and 15% and 20% for OARs according to the observed levels. In each group simulation, five uncertainties were produced randomly for five HDR brachytherapy. Each simulated fractional dose was transformed into biologically equivalent dose in 2Gy fractions (EQD2), and thereafter all fractions were added and summed up with the EBRT EQD2 dose in order to obtain total EBRT + BT EQD2 dose. Results of the 4,000 simulations were evaluated and compared with the expected dose.

Statistical analysis

A total of 76 image series were obtained for patients enrolled in this group, including 38 planning CT image series and 38 pre-delivery CBCT image series as shown in supplementary file 1. DVH parameters of HRCTV and OARs were collected and tested for normality. If they were in accordance with the normality test, the t-test was used for analysis. Wilcoxon signed rank sum test was performed if they were non-normally distributed. All the tests were two-sided, with P < 0.05 considered statistically significant. Statistical analysis was performed using SPSS 23.0 (IBM Corp, NY, USA).

Results

The relative systematic and random variations of HRCTV and OARs between planning CT and pre-delivery CBCT are reported as mean (± SD uncertainties) in percentage in Table 1. Note that a positive difference indicates that the pre-delivery CBCT value is greater than the planning CT value. The mean time interval between the planning CT and pre-delivery CBCT acquisition was 53min (range 39-92min).

1. Dosimetric variation for HRCTV

The mean (± SD) variations between the planning CT and pre-delivery CBCT images were -2.00 ± 3.26% for the HR CTV volume (P < 0.001) and 1.18% ± 4.47% for D90 physical dose (P > 0.05). The proportion of D90 dose difference within ± 5% is 76.32% (29/38), and the proportion exceeding ±10% is only 7.89%

(3/38) with a maximum change of -12.71% (Fig. 1). The mean ($\pm$ SD) variation of D90 (EQD2) is $1.16 \pm 6.09\%$ ($P > 0.05$), and the maximum value of absolute change is 1.56Gy. The proportion of changes within ± 0.5 Gy was 73.68% (28/38), and the proportion of changes exceeding ± 1 Gy was 10.53% (4/ 38).

2. Dosimetric variation for OARs

The mean values and variation of the structure volume and DVH parameter between the planning CT and pre-delivery CBCT for OARs are presented in Table 1. The mean ($\pm$ SD) changes in structure volume, D2cc physical dose and EQD2 was $-6.89 \pm 34.09\%$, $9.34 \pm 14.59\%$ and $11.3 \pm 31.91\%$ for the rectum, which was statistically different ($P < 0.05$). No statistically significant differences were found in the variations of structure volumes, D2cc physical dose and EQD2 for bladder, sigmoid and small intestine (all $P > 0.05$). The mean value in the DVH parameters of bladder and small intestine were within $\pm 3\%$ for the D2cc physical dose and $\pm 5\%$ for the EQD2 dose. However, large variations up to 1.7Gy was observed for the D2cc physical dose of bladder.

Fig. 2 & 3 presents the histogram of the number of fractions for relative difference in the DVH parameters for OARs. The average volume variation and uncertainty of sigmoid tended to be higher than other OARs. The relative volume differences exceeding 20% were found for 34.2% of the fractions in the sigmoid. For most of the fractions, the relative physical dose differences were within $0\% \pm 15\%$; however, the relative dose differences exceeding 20% were found for 15.8% of the fractions in the bladder, 21.1% of those in the rectum, 18.4% of those in the sigmoid, and 10.5% of those in the small intestine. The maximum physical dosimetric variation was 37.6% for the bladder, 28.1% for the rectum, 77.0% for sigmoid and 33.2% for the small intestine.

3. Probability distribution of the total dose based on dosimetric uncertainty

3.1 HR CTV

Results of the simulation of total treatment dose in EQD2, taking into account the dosimetric uncertainties of individual BT fractions are shown in Table 2. For a random uncertainty of 5%, the mean ($\pm$ SD) total simulated dose is 89.56 ± 1.24 Gy. There were 31.7% probability that total simulated dose less than 89Gy, and 2% probability that total simulated dose less than 87Gy. The probability that the total dose is less than 85Gy is close to 0%. A random uncertainty of 10% lead to random uncertainties (SD) of the total simulated dose of 89.70 ± 2.48 Gy. The probability that the total dose is less than 89Gy is 40%. There were 15% probability that total simulated dose was less than 87Gy, and 3% probability that total simulated dose was less than 85Gy.

3.2 OARs

In this study, the average D2cc dose of OARs was about 3.5Gy. The uncertainty in a single fraction of D2cc physical dose for OARs was about 15% and 20%. The similar simulation process was carried out for the OARs taking into account the dosimetric uncertainties, as shown in Table 3. The probability of EQD2

exceeding 75Gy was about 6% and 14% in rectum, sigmoid and small intestine, respectively. Less than 1% of the total EQD2 of OARs would exceed 80Gy.

In fact, the average physical dose of D2cc in bladder, rectum and small intestine was about 4Gy. Therefore, the simulation process was repeated again at an average dose of 4Gy, as shown in the Table 3. Under the uncertainties of 15% and 20%, the probability of the intestinal D2cc EQD2 exceeding 75Gy is about 70%, and the probability of exceeding the 80Gy is about 10% and 20%, respectively.

Discussion

In terms of HRCTV, the average volume depicted on CBCT was smaller than that depicted on CT. However, the absolute difference is only about 1cc, which has little on the dosimetric variation. Considering the accuracy and contouring error of different planning systems, this significant difference mainly affects D98 HRCTV, while the impact on D90 HRCTV can be ignored [28]. The systematic and random variation of D90 HRCTV in our study were lower than $-2.5 \pm 10.8\%$ reported by Nesvacil et al. [24]. The possible reason was that the time interval between two image scans in this study was much shorter. Besides, the applicator and the HRCTV were usually fixed together resulting in a constant relative position between them. Therefore, the deformation of HRCTV on the main DVH parameters can be ignored.

The average dose change of the bladder was only -0.6% , which was lower than 9.34% of the rectum. In addition, the average difference of bladder volume between planning and pre-delivery images was only 0.30cc with no significant difference ($P > 0.05$). Similarly, urinary catheters were used in all cases and resulted in a lower dosimetric variation in the bladder than the rectum in the study of Andersen et al. [29]. With only 48% patients undergoing bladder preparation, Miyasaka et al. found a greater D2cc variation for the bladder than that of the rectum due to the accumulation of urine [12]. Therefore, most patients emptied their bladder and were catheterized to reduce the bladder dose in this study [30, 31]. However, this was contradicted with the recommendation that maintaining the standardized bladder volume can reduce the variation of bladder dose [27]. In addition, the full bladder pushed the intestine upward and thus protects the small intestine since the constraint dose for the intestine was lower than the that for bladder [9, 32]. Zahra et al. found that the full bladder would increase the dose in rectum and sigmoid colon when tandem $> 4\text{cm}$ [33]. While keeping the bladder full tended to result in a lower dose to rectum and sigmoid for tandems shorter than 4 cm. In general, the relationship between bladder and other OARs, and the length of tandem should be taken into consideration during HDR BT.

Unlike the bladder, the rectum expands and contracts in the anterior-to-posterior direction due to gas movement. Much of the variation in the rectum was in the direction of dose reduction [12, 29]. In our study, the volume of rectum decreased from planning CT to pre-delivery CBCT while the D2cc increased. We found that the rectum on pre-delivery CBCT was closer to HRCTV in the anterior-to-posterior direction, although no quantitative analysis on the movement of rectum was performed. It could be assumed that a larger space left by the empty bladder allowed the rectum to be closer to HRCTV after planning CT scanning. Measures such as pre-delivery verification and rectal catheters could be used to avoid

excessive rectal dose for long interval between treatment planning and delivery. Nomdem et al. found that rectal catheters help to reduce rectal dose, and even steps to control gas in the rectum might effectively prevent accidental changes in organs [13].

Our simulations of delivered dose ranges for an example of a treatment with 6Gy×5 HDR BT evaluate the possibility of reaching the prescribed dose. In terms of D90 HRCTV, a dose of $\geq 85\text{Gy}$ results in a local control rate of $> 93\%$ in intermediate size targets (HRCTV 20-30cm³) and $> 86\%$ in large targets (HRCTV 30- 70cm³) at brachytherapy[24]. Another study by Domopoulos et al. [34] on the relationship between DVH parameters and local control rate found that the local control rate can reach $> 95\%$ at a D90 HRCTV dose of $\geq 87\text{Gy}$. In this study, at the uncertainty level of 10% in single fraction, the probability of total D90 EQD2 $< 87\text{Gy}$ is about 15%, and 3% for D90 EQD2 $< 85\text{Gy}$. There is a risk that the received dose is lower than the recommended dose at an uncertainty of 10%. When increasing deliver dose to 6.2Gy each fraction, the probability of total EQD2 of $< 87\text{Gy}$ and $< 85\text{Gy}$ is about 3% and 0.3% at an uncertainty level of 10%, respectively. It should be noted that this result is only applicable to 5 fractions HDR BT and a 50.4Gy/28f external irradiation. In the study of Nesvacil et al. [14], an uncertainty of 10% and a total EQD2 of 90Gy would result in a dose uncertainties of 3.3Gy in the 7Gy×4 HDR BT. In our study, the corresponding dose uncertainty is 2.5Gy in the 6Gy×5 HDR BT at an uncertainty of 10% and a total EQD2 of 90Gy.

Controlling the D2cc EQD2 dose of bladder, rectum, sigmoid colon and small intestine lower than 90Gy, 75Gy, 75Gy and 75Gy can reduce the incidence of complications [35]. Our simulation results suggest that the probability of exceeding the constraint dose is less than 0.1% for EQD2 of bladder due to its high radiation tolerance. The sigmoid had the highest average D2cc uncertainty of 20%, which is consistent with the high mobility of sigmoid colon [36]. When the average applied dose is 4Gy, the possibility of exceeding 75Gy is 68% for EQD2 of the sigmoid. In the absence of definite data regarding the sigmoid toxicity and the high uncertainty [35], there is no need to compromise the HRCTV dose to keep the sigmoid dose within limits [15]. Although the uncertainty of rectum is lower than that of sigmoid (15% vs 20%), there might be a large variation in the total EQD2 dose of the rectum and recto-sigmoid junction due to the high average dose. Pre-delivery re-scanning helps to identify unfavorable movement and volumes change of bladder and rectum [12, 15]. What's more, active preliminary treatment such as inserting catheter was recommended to control bladder volume or rectal gas to reduce intra-fractional variations.

There were some limitations to this study. First, this is a single-institution study with a small sample size that included only 9 participants (38 HDR fractions). Whether patient characteristics and treatment plans would cause dosimetric variation could not be valued. For example, none of the patients were catheterized for the rectum and the same fraction schedule was used in this study. Further studies with larger sample sizes from multiple institutions are needed to compare the difference between different preparations and treatment plans. Second, different imaging techniques were used for treatment planning and pre-delivery rescanning in order to limit the motion of patients and shorten the time interval. Uniform image technique could be used to reduce the intra-observer variation, and the patients would be

able to received radiation in situ in such modality. Third, CBCT images include larger amounts of scattering and poorer resolution than CT, making it difficult for drawing organ wall contours and calculating the maximal dose precisely [37]. Although our result showed the possibility of CBCT for contouring and direct dose calculation, specialized calibrations and optimizations to reduce scattering should be considered in further studies.

Conclusion

In conclusion, our results quantified the volume and dose changes caused by intra-fractional variation. The volume and relative position to applicator of HRCTV was stable in a short time interval leading to a small intra-fractional dosimetric variation. Most variations of the D90 EQD2 are within a clinical acceptable level and the possibility of total EQD2 exceeding 85Gy is higher than 97%. Due to the greater changes of position and volume, the intra-fractional dosimetric variation of OARs was higher than that of HRCTV. This might result in an overdose in a single fraction or the constraint of individual OAR for the whole treatment (includes EBRT). Our finding supported the necessity to detect unfavorable anatomical changes by re-imaging prior to dose delivery. Interventions should be taken into consideration to minimize delivered doses and reduce the risks of complications, especially when the planning DVH parameters of rectum and small intestine were close to the limits.

Abbreviations

HRCTV: High-risk Clinical Target Volume; OAR: Organ At Risk; EBRT: External Beam Radiotherapy; BT: Brachytherapy. 3D-IGABT: Three-dimensional Image-guided Adaptive Brachytherapy; CT: Computed Tomography; CBCT: Cone-beam Computed Tomography; MRI: Magnetic Resonance Imaging; EQD2: Equivalent Dose in 2 Gy/f; DVH: Dose-volume Histogram; HDR: High-dose-rate.

Declarations

Ethics approval and consent to participate

The Institutional Review Board (IRB) of Peking Union Medical College Hospital (PUMCH) reviewed the protocol. The protocol is rational and scientific. The study accords with principle of ethics and the IRB approve the protocol. Written human subject consent was obtained.

Consent for publication

No applicable, as no individual patient data has been published.

Availability of data and materials

Owing to data privacy policy at our facility, publication of patient-related raw data is not possible.

Competing interests

The authors have no conflict of interest to disclose.

Funding

This work was funded by the Education Reform Program (No. 2020zlgc0124) of Peking Union Medical College and the National Key Research and Development Plan, the Ministry of Science and Technology of the People's Republic of China (No. 2016YFC0105207). There was no financing from public funds or from third parties.

Author Contributions

JF.Y, JW.Z and K.C collected, analyzed, and interpreted the data. JF.Y and JW.Z wrote the manuscript. K.C, L.Y and FQ.Z reviewed and edited the manuscript. JF.Y, L.Y and FQ.Z designed and supervised the study. FQ.Z has full access to all the data in the study and final responsibility for the decision to submit for publication. All authors read and approved the final manuscript.

Acknowledgements

We appreciate the support of PUMCH and the effort of every medical staff who have treated these patients.

References

1. Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S *et al*: **NCCN Guidelines Insights: Cervical Cancer, Version 1.2020**. *J Natl Compr Canc Netw* 2020, **18**(6):660-666.
2. Lin AJ, Kidd E, Dehdashti F, Siegel BA, Mutic S, Thaker PH, Massad LS, Powell MA, Mutch DG, Markovina S *et al*: **Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer**. *Int J Radiat Oncol Biol Phys* 2019, **103**(5):1088-1097.
3. Charra-Brunaud C, Harter V, Delannes M, Haie-Meder C, Quetin P, Kerr C, Castelain B, Thomas L, Peiffert D: **Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study**. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology* 2012, **103**(3):305-313.
4. Pötter R, Dimopoulos J, Georg P, Lang S, Waldhäusl C, Wachter-Gerstner N, Weitmann H, Reinthaller A, Knoke TH, Wachter S *et al*: **Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer**. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology* 2007, **83**(2):148-155.
5. Castelnau-Marchand P, Chargari C, Maroun P, Dumas I, Del Campo ER, Cao K, Petit C, Martinetti F, Tafo-Guemnie A, Lefkopoulos D *et al*: **Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer**. *Gynecol Oncol* 2015, **139**(2):288-294.

6. Zolciak-Siwinska A, Kowalczyk A, Sikorska K, Bijok M, Michalski W, Gruszczynska E: **Comparison of computed tomography with magnetic resonance imaging for imaging-based clinical target volume contours in cervical cancer brachytherapy.** *Brachytherapy* 2018, **17**(4):667-672.
7. Viswanathan AN, Erickson B, Gaffney DK, Beriwal S, Bhatia SK, Lee Burnett O, 3rd, D'Souza DP, Patil N, Haddock MG, Jhingran A *et al*: **Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancer.** *Int J Radiat Oncol Biol Phys* 2014, **90**(2):320-328.
8. Grover S, Harkenrider MM, Cho LP, Erickson B, Small C, Small W, Jr., Viswanathan AN: **Image Guided Cervical Brachytherapy: 2014 Survey of the American Brachytherapy Society.** *Int J Radiat Oncol Biol Phys* 2016, **94**(3):598-604.
9. Patra NB, Manir KS, Basu S, Goswami J, Kabasi AK, Sarkar SK: **Effect of bladder distension on dosimetry of organs at risk in computer tomography based planning of high-dose-rate intracavitary brachytherapy for cervical cancer.** *J Contemp Brachytherapy* 2013, **5**(1):3-9.
10. Choong ES, Bownes P, Musunuru HB, Rodda S, Richardson C, Al-Qaisieh B, Swift S, Orton J, Cooper R: **Hybrid (CT/MRI based) vs. MRI only based image-guided brachytherapy in cervical cancer: Dosimetry comparisons and clinical outcome.** *Brachytherapy* 2016, **15**(1):40-48.
11. Wang F, Tang Q, Lv G, Zhao F, Jiang X, Zhu X, Li X, Yan S: **Comparison of computed tomography and magnetic resonance imaging in cervical cancer brachytherapy: A systematic review.** *Brachytherapy* 2017, **16**(2):353-365.
12. Miyasaka Y, Kadoya N, Ito K, Umezawa R, Kubozono M, Yamamoto T, Nakajima Y, Saito M, Takayama Y, Nemoto K *et al*: **Quantitative analysis of intra-fractional variation in CT-based image guided brachytherapy for cervical cancer patients.** *Phys Med* 2020, **73**:164-172.
13. Nomden CN, de Leeuw AA, Roesink JM, Tersteeg RJ, Westerveld H, Jurgenliemk-Schulz IM: **Intra-fraction uncertainties of MRI guided brachytherapy in patients with cervical cancer.** *Radiother Oncol* 2014, **112**(2):217-220.
14. Nesvacil N, Tanderup K, Hellebust TP, De Leeuw A, Lang S, Mohamed S, Jamema SV, Anderson C, Potter R, Kirisits C: **A multicentre comparison of the dosimetric impact of inter- and intra-fractional anatomical variations in fractionated cervix cancer brachytherapy.** *Radiother Oncol* 2013, **107**(1):20-25.
15. Simha V, Patel FD, Sharma SC, Rai B, Oinam AS, krishnatry R, Dhanireddy B: **Evaluation of intrafraction motion of the organs at risk in image-based brachytherapy of cervical cancer.** *Brachytherapy* 2014, **13**(6):562-567.
16. Anderson C, Lowe G, Wills R, Inchley D, Beenstock V, Bryant L, Chapman C, Hoskin PJ: **Critical structure movement in cervix brachytherapy.** *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology* 2013, **107**(1):39-45.
17. Heijkoop ST, Langerak TR, Quint S, Bondar L, Mens JW, Heijmen BJ, Hoogeman MS: **Clinical implementation of an online adaptive plan-of-the-day protocol for nonrigid motion management in locally advanced cervical cancer IMRT.** *Int J Radiat Oncol Biol Phys* 2014, **90**(3):673-679.

18. Sharfo AW, Breedveld S, Voet PW, Heijkoop ST, Mens JM, Hoogeman MS, Heijmen BJ: **Validation of Fully Automated VMAT Plan Generation for Library-Based Plan-of-the-Day Cervical Cancer Radiotherapy.** *PLoS One* 2016, **11**(12):e0169202.
19. Al-Halabi H, Portelance L, Duclos M, Reniers B, Bahoric B, Souhami L: **Cone beam CT-based three-dimensional planning in high-dose-rate brachytherapy for cervical cancer.** *Int J Radiat Oncol Biol Phys* 2010, **77**(4):1092-1097.
20. Mason SA, White IM, O'Shea T, McNair HA, Alexander S, Kalaitzaki E, Bamber JC, Harris EJ, Lalondrelle S: **Combined Ultrasound and Cone Beam CT Improves Target Segmentation for Image Guided Radiation Therapy in Uterine Cervix Cancer.** *Int J Radiat Oncol Biol Phys* 2019, **104**(3):685-693.
21. Lowther NJ, Marsh SH, Louwe RJW: **Quantifying the dose accumulation uncertainty after deformable image registration in head-and-neck radiotherapy.** *Radiother Oncol* 2020, **143**:117-125.
22. Veiga C, McClelland J, Moinuddin S, Lourenço A, Ricketts K, Annkah J, Modat M, Ourselin S, D'Souza D, Royle G: **Toward adaptive radiotherapy for head and neck patients: Feasibility study on using CT-to-CBCT deformable registration for "dose of the day" calculations.** *Med Phys* 2014, **41**(3):031703.
23. Pearson D, Gill SK, Campbell N, Reddy K: **Dosimetric and volumetric changes in the rectum and bladder in patients receiving CBCT-guided prostate IMRT: analysis based on daily CBCT dose calculation.** *Journal of applied clinical medical physics* 2016, **17**(6):107-117.
24. Pötter R, Tanderup K, Kirisits C, de Leeuw A, Kirchheiner K, Nout R, Tan LT, Haie-Meder C, Mahantshetty U, Segedin B *et al*: **The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies.** *Clin Transl Radiat Oncol* 2018, **9**:48-60.
25. Haie-Meder C, Pötter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, Dumas I, Hellebust TP, Kirisits C, Lang S *et al*: **Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.** *Radiother Oncol* 2005, **74**(3):235-245.
26. Pötter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, Dumas I, Erickson B, Lang S, Nulens A *et al*: **Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.** *Radiother Oncol* 2006, **78**(1):67-77.
27. Lang S, Nulens A, Briot E, Kirisits C, De Brabandere M, Dumas I, Dimopoulos J, Petrow P, Georg D, Van Limbergen E *et al*: **Intercomparison of treatment concepts for MR image assisted brachytherapy of cervical carcinoma based on GYN GEC-ESTRO recommendations.** *Radiother Oncol* 2006, **78**(2):185-193.
28. Morcos M, Antaki M, Viswanathan AN, Enger SA: **A novel minimally invasive dynamic-shield, intensity-modulated brachytherapy system for the treatment of cervical cancer.** *Med Phys* 2020.

29. Anderson C, Lowe G, Wills R, Inchley D, Beenstock V, Bryant L, Chapman C, Hoskin PJ: **Critical structure movement in cervix brachytherapy.** *Radiother Oncol* 2013, **107**(1):39-45.
30. Kim RY, Shen S, Lin HY, Spencer SA, De Los Santos J: **Effects of bladder distension on organs at risk in 3D image-based planning of intracavitary brachytherapy for cervical cancer.** *Int J Radiat Oncol Biol Phys* 2010, **76**(2):485-489.
31. Yamashita H, Nakagawa K, Okuma K, Sakumi A, Haga A, Kobayashi R, Ohtomo K: **Correlation between bladder volume and irradiated dose of small bowel in CT-based planning of intracavitary brachytherapy for cervical cancer.** *Jpn J Clin Oncol* 2012, **42**(4):302-308.
32. Ju SG, Huh SJ, Shin JS, Park W, Nam H, Bae S, Oh D, Hong CS, Kim JS, Han Y *et al*: **Different effects of bladder distention on point A-based and 3D-conformal intracavitary brachytherapy planning for cervical cancer.** *J Radiat Res* 2013, **54**(2):349-356.
33. Siavashpour Z, Aghamiri MR, Jaber R, ZareAkha N, Manshadi HRD, Kirisits C, Sedaghat M: **A comparison of organs at risk doses in GYN intracavitary brachytherapy for different tandem lengths and bladder volumes.** *J Appl Clin Med Phys* 2016, **17**(3):5-13.
34. Dimopoulos JC, Lang S, Kirisits C, Fidarova EF, Berger D, Georg P, Dörr W, Pötter R: **Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy.** *Int J Radiat Oncol Biol Phys* 2009, **75**(1):56-63.
35. Pötter R, Tanderup K, Kirisits C, de Leeuw A, Kirchheiner K, Nout R, Tan LT, Haie-Meder C, Mahantshetty U, Segedin B *et al*: **The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies.** *Clin Transl Radiat Oncol* 2018, **9**:48-60.
36. Sturdza AE, Berger D, Lang S, Dimopoulos J, Thomas G, Georg P, Kirisits C, Poetter R: **Uncertainties in assessing sigmoid dose volume parameters in MRI-guided fractionated HDR brachytherapy.** *Brachytherapy* 2008, **7**(2):109.
37. Stock M, Pasler M, Birkfellner W, Homolka P, Poetter R, Georg D: **Image quality and stability of image-guided radiotherapy (IGRT) devices: A comparative study.** *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology* 2009, **93**(1):1-7.

Tables

Table 1. Dosimetric variations between planning CT and pre-delivery CBCT

	CT	CBCT	Variation	Range of difference	P
HRCTV					
Volume (cc)	54.14±17.17	53.08±16.85	-2.00±3.26%	0.02-6.76	<0.001
D90 (cGy)	606.35±39.29	599.12±45.79	1.18±4.47%	0.07-79.08	0.120
D90 (EQD2, cGy)	812.95±72.63	800.10±83.56	1.16±6.09%	0.12-156.02	0.139
Bladder					
Volume (cc)	81.38±53.46	81.67±47.98	7.86±36.68%	0.31-146.10	0.957
D2cc (cGy)	391.56±74.76	389.24±71.85	-1.09±17.05%	1.80-167.78	0.810
D2cc (EQD2, cGy)	552.46±151.06	542.62±151.23	2.67±26.57%	4.23-355.15	0.772
Rectum					
Volume (cc)	46.21±13.93	41.87±15.48	-6.89% ±34.09%	0.02-22.53	0.001*
D2cc (cGy)	302.89±84.37	327±86.88	9.34±14.59%	0.56-168.01	0.001*
D2cc (EQD2, cGy)	379.08±157.05	425.71±169.32	15.01±23.99%	0.73-336.16	0.001*
Sigmoid					
Volume (cc)	24.77±15.72	24.28±11.11	19.93±68.16%	0.16-48.87	0.763
D2cc (cGy)	301.45±85.76	312.53±74.56	7.15±20.49%	1.73-130.32	0.127
D2cc (EQD2, cGy)	376.93±146.62	393.70±130.38	11.35±31.91%	2.81-210.39	0.192
Small Intestine					
Volume (cc)	400.98±115.02	394.04±145.73	-0.52±26.74%	2.26-360.65	0.705
D2cc (cGy)	411.19±60.28	418.18±83.36	1.52±12.57%	0.78-138.75	0.422
D2cc (EQD2, cGy)	591.94±130.91	614.18±190.04	3.36±20.65%	2.02-353.62	0.293

*P < 0.05

Table 2. Dosimetric simulation of the D90 HRCTV (EQD2)

Uncertainty level	5%	10%
EQD2(Gy)	89.56±1.24	89.70±2.48
≥90Gy	63.03%	55.56%
≥89Gy	31.73%	38.80%
≥88Gy	10.18%	25.13%
≥87Gy	1.88%	13.53%
≥86Gy	0.20%	6.08%
≥85Gy	0.03%	2.75%
≥80Gy	0	0

Table 3. Dosimetric simulation of the OARs D2cc (EQD2)

Dose level	3.5Gy		4Gy	
Uncertainty level	15%	20%	15%	20%
EQD2(Gy)	71.32±2.36	71.61±3.14	76.68±2.96	77.02±4.02
>75Gy	5.83%	13.73%	71.28%	68.00%
>76Gy	2.73%	8.15%	58.48%	58.93%
>77Gy	1.01%	4.73%	45.15%	49.40%
>78Gy	0.4%	2.5%	32.25%	39.38%
>79Gy	0.08%	1.23%	21.50%	30.13%
>80Gy	0	0.6%	12.60%	22.45%
>85Gy	0	0	0.28%	3.18%
>90Gy	0	0	0	0.08%

Figures

Histogram of HRCTV

Figure 1

The histogram of the number of fractions for relative difference in the HRCTV volume and D90.

Histogram of OARsVolume

Figure 2

The histogram of the number of fractions for relative volume difference of OARs.

Figure 3

The histogram of the number of fractions for relative physical dose difference in the D2cc of OARs.